Drug Discovery & Development
Drug Discovery & Development provides insight into innovative strategies and technologies used by researchers to drive drug discovery to market. Through its newsletter and www.dddmag.com, the publication delivers:
• Discussions, from informed voices in the pharmaceutical and biotechnology community, on applications for developing new therapies
• Detailed examinations of trends and technologies in genomics and proteomics
• Engaging, practical applications of tools and techniques that enhance processes from early-stage discovery through development and clinical testing
• Unique perspectives on trends, regulatory issues, technologies, and news that drive the dynamics of drug discovery and development
The readers of Drug Discovery & Development and www.dddmag.com are researchers, scientists and lab managers, and corporate managers in pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic, medical, government, and contract research organizations. They know technology is critical to their work and turn to Drug Discovery & Development and www.dddmag.com to find the information they need to improve their day-to-day research.
Feature articles, application reviews, case studies, and research summaries are authored by the magazine’s editors and experts in the industry. The editors invite contributions from researchers and scientists in pharma, biotech, and academic settings. Contributions from technical specialists in vendor communities are welcome, but must adhere to editorial guidelines for objective, noncommercial writing.
Articles must be objective and can not promote any company or its products/services. All statements about performance or claims must be supported by references to published literature.
Manuscripts or abstracts should not have been published previously and should be submitted to Drug Discovery & Development on an exclusive basis. All manuscripts are subject to review and editing. The editorial staff makes all decisions regarding publication of articles.
Authors must obtain all internal clearances for articles prior to submission for publication. Authors are responsible for all statements made in their work.
Authors are responsible for obtaining written reprint permission for illustrations and data previously published; crediting information and captions must be provided.
All published articles are copyrighted by Advantage Business Media and may only be used for other purposes with written approval of Advantage Business Media/Drug Discovery & Development Magazine or www.DDDmag.com.
Images should focus on experimental results, including charts and displays from instruments or software, flow diagrams, or photos of individuals referenced in the text in a work environment.
References to illustrations, tables, and images should be identified in the proper position in the text of the article (as figure 1, table 1, etc.) and submitted as separate, clearly identified files (as figure 1, table 1, etc.). Captions and credits should be listed at the end of the article.
References should be numbered consecutively in the text and listed at the end of the article following AMA style.
Research/Technology Reviews provide a journalistic overview of emerging technologies or new applications for current technologies for drug discovery, drug development, genomics, and proteomics.
These features do not focus on a particular product or vendor, but provide a broader, industry-wide look at techniques and technologies. Length: up to 800 words
Facility Profiles provide an in-depth tour of a specific research facility or organization engaged in drug discovery and development, reviewing how technologies or processes are used.
Business/Finance and Legal/Regulatory issues that impact research activities are addressed periodically.
How It Works features explain how a technology or process works, describing the science and theory, as well as practical applications. The discussion should avoid standard product announcement or marketing descriptions. How It Works topics are selected on a quarterly basis.
Drug Pipeline features describe the development of the drug, the mechanism of action, and the status of any trials or studies.
Article Submission Process
Ideas for articles should be submitted to the editors in advance. Submit a brief abstract and a list of proposed illustrations and graphics. After review, the editors will specify a word count and submission deadline. The editors will contact authors regarding the submitted proposals a few weeks after submission.
All submissions should include the author’s name, title, company, 50-word biography, address, phone, email, and website address. If appropriate, include contact information at a representative public relations or marketing agency.
Article abstracts and inquiries should be submitted to: email@example.com.
News and Product Releases
Drug Discovery & Development accepts news and product release information for publication in the magazine and on the website. The content is edited at the discretion of the editors. News and product information appear on the website within one week of submission and in print approximately two months after submission.
Product, news, and press releases should be submitted via email to firstname.lastname@example.org.
Product releases should be specific for the drug discovery and development market. Submit information on products that are new (introduced in the last month). Describe the features, basic technical specifications, benefits, applications, and any significant improvements over a previous version of the product. Include links to additional documentation. Include an image of the product as a separate file. Length: 250-300 words.
News releases should report business news from an organization involved in drug discovery and development. Topics include acquisitions, mergers, partnerships, contracts, new clinical trials, research studies, new drug launches, personnel promotions, and other business activities.
All releases should include a contact name, address, phone number, e-mail address, website address, and release date.
Drug Discovery & Development honors all embargoed release dates clearly indicated on press releases.
Due to the volume of releases, we cannot confirm publication of individual releases. Please check www.dddmag.com to see if a release has been published.
How to Submit
Text File Types: Microsoft Word or rich-text format. Send as an email attachment scanned for viruses.
Images/Art: Images should be submitted as separate files. Do not embed images in text documents, PowerPoint files, or emails. Images should be at least 250 p wide. File types accepted:
• TIFF (.tif)
• JPEG (.jpg)
• Bitmap (.bmp)
• Encapsulated Post Script (.eps)
• Adobe Portable Document Format (.pdf)
Press releases, general inquiries:
Editor-in-Chief, Drug Discovery & Development